Site Editor

Sandy Srinivas, MD

Advertisement

Advertisement

News

Novel Gene Signature May Predict the Risk of Lineage Plasticity in Prostate Tumors

Medical Literature

Rezvilutamide or Bicalutamide: Which Is a Better Partner for Androgen-Deprivation Therapy?

News

ASTRO 2022: Quality of Life and Quantity of Life in Patients With Prostate Cancer

Medical Literature

Change in Public Messaging May Dispel Common Misconception and Improve Outcomes in Prostate Cancer

Medical Literature

Can Drinking Coffee Improve Survival in Prostate Cancer?

News

ASTRO 2022: Using 24-Gene Score to Predict Outcomes With Salvage Radiotherapy After Radical Prostatectomy

News

ASTRO 2022: Multimodal Deep Learning Versus NCCN Risk Stratification of Prostate Cancer

Felix Y. Feng, MD, on Predicting the Efficacy of Apalutamide in Patients With Castration-Resistant Prostate Cancer

Sandy Srinivas, MD, on Balancing Quality of Life and Survival When Making Decisions About Prostate Cancer Treatment

View More

Advertisement

JNCCN Spotlights

(UPDATE September 2022) Enzalutamide

(UPDATE) Degarelix (Injectable GnRH Antagonist)

Docetaxel (Castration-Naive Metastatic Prostate Cancer)

UPDATE October 2020 Enzalutamide

Degarelix (Injectable GnRH Antagonist)

(UPDATE) Apalutamide in Prostate Cancer

View More

More

News

What Can Be Learned From ctDNA About Treatment-Resistant Prostate Cancer? Researchers Say a Lot

FDA Approves Darolutamide Combination for Metastatic Hormone-Sensitive Prostate Cancer

Are LHRH Antagonists Indicated for Patients With Prostate Cancer at High Cardiovascular Risk?

FDA Grants Priority Review to Olaparib-Based Combination for Metastatic Castration-Resistant Prostate Cancer

ASTRO 2022: PSMA PET/CT and Its Impact on Prostate Cancer Salvage Radiation Therapy Management

Targeted Imaging With PSMA Tracer May Alter Treatment Plans for Some Patients With Prostate Cancer

ASCO Quality 2022: Tailored Self-Managed Care for Survivors of Prostate Cancer

ASTRO 2022: Using 24-Gene Score to Predict Outcomes With Salvage Radiotherapy After Radical Prostatectomy

View More

Advertisement

Published

Medical Literature

Researchers Offer Evidence That Prostate Cancer Biology May Differ by Racial Ancestry

Adding Darolutamide to Standard Treatment in Metastatic, Hormone-Sensitive Prostate Cancer

Enzalutamide Monotherapy: Active Surveillance Alternative in Low- or Intermediate-Risk Prostate Cancer?

Can the Number of Positive Pelvic Lymph Nodes Guide Adjuvant Radiation Therapy for Prostate Cancer?

View More

Ongoing

CE Activities

Oncology Today with Dr Neil Love: Key Presentations on Genitourinary Cancers from the 2022 ASCO Annual Meeting

Talk to Someone: Explore Talking to Patients About Prostate Cancer Treatment

How Will You Manage These Patients With Prostate Cancer? Practice Your Skills in This Virtual Patient Simulation

Patient Simulations in Personalized Planning for Prostate Cancer

View More

Available

Clinical Trials

University of Nebraska

Seidman Cancer Center

City of Hope

Dana-Farber Cancer Institute

View More

Resources

For Your Patients

Urology Care Foundation

Cancer Support Community

Prostate Cancer Foundation

NCCN Guidelines for Patients®: Prostate Cancer: Early Stage

View More

Sections

360 Hub

NCCN Resources

Copyright^© 2022 National Comprehensive Cancer Network, All Rights Reserved

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.